7X7O

SARS-CoV-2 spike RBD in complex with neutralizing antibody UT28K

Summary for 7X7O

• Entry DOI: 10.2210/pdb7x7o/pdb
• Descriptor: Spike protein S1, UT28K Fab, heavy chain, UT28K Fab, light chain (3 entities in total)
• Functional Keywords: sars-cov-2, spike, antibody, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2; More
• Total number of polymer chains: 12
• Total formula weight: 310251.80

Authors

Ozawa, T.,Tani, H.,Anraku, Y.,Kita, S.,Igarashi, E.,Saga, Y.,Inasaki, N.,Kawasuji, H.,Yamada, H.,Sasaki, S.,Somekawa, M.,Sasaki, J.,Hayakawa, Y.,Yamamoto, Y.,Morinaga, Y.,Kurosawa, N.,Isobe, M.,Fukuhara, H.,Maenaka, K.,Hashiguchi, T.,Kishi, H.,Kitajima, I.,Saito, S.,Niimi, H. (deposition date: 2022-03-10, release date: 2022-05-25, Last modification date: 2024-10-23)

Primary citation

Ozawa, T.,Tani, H.,Anraku, Y.,Kita, S.,Igarashi, E.,Saga, Y.,Inasaki, N.,Kawasuji, H.,Yamada, H.,Sasaki, S.I.,Somekawa, M.,Sasaki, J.,Hayakawa, Y.,Yamamoto, Y.,Morinaga, Y.,Kurosawa, N.,Isobe, M.,Fukuhara, H.,Maenaka, K.,Hashiguchi, T.,Kishi, H.,Kitajima, I.,Saito, S.,Niimi, H.
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.
Mabs, 14:2072455-2072455, 2022

PubMed Abstract: Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an assay and prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

PubMed: 35543180
DOI: 10.1080/19420862.2022.2072455

Experimental method

X-RAY DIFFRACTION (3.75 Å)